Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Design Therapeutics ( (DSGN) ).
On June 10, 2025, Design Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders, where stockholders voted on key matters. The election of three Class I Directors was confirmed, with Heather Berger, Ph.D., Rodney Lappe, Ph.D., and John Schmid elected to serve until the 2028 Annual Meeting. Additionally, the stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (DSGN) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Design Therapeutics stock, see the DSGN Stock Forecast page.
Spark’s Take on DSGN Stock
According to Spark, TipRanks’ AI Analyst, DSGN is a Neutral.
Design Therapeutics has significant financial challenges due to its lack of revenue and profitability, which heavily weighs on its score. Despite a strong balance sheet and positive technical indicators suggesting short-term momentum, the negative valuation metrics and absence of earnings diminish its overall appeal. The stock is risky and reliant on future revenue growth for improvement.
To see Spark’s full report on DSGN stock, click here.
More about Design Therapeutics
Average Trading Volume: 117,988
Technical Sentiment Signal: Sell
Current Market Cap: $227.6M
Find detailed analytics on DSGN stock on TipRanks’ Stock Analysis page.